RxDoctor Payments Data

Dane Petersen, NP

Nurse Practitioner · Ventura, CANPI 1033881669

Payments from drug & device makers

$8,202in general payments, 2019–2025

Across 75 payments — averaging $109.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Merck$263
  • Edwards Lifesciences$214
  • Boston Scientific$195
  • Amgen$136
  • AstraZeneca$100
  • plus $580 from 11 others

What the payments were for

  • Speaking & faculty fees$6,71382%
  • Food & beverage$1,48918%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,202 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$42,191
Medicare patients
216
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$15,868
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,518
TrulicityDulaglutide14$13,163
JardianceEmpagliflozin13$11,504
XareltoRivaroxaban17$11,006
JanuviaSitagliptin Phosphate13$10,575
Breo ElliptaFluticasone/Vilanterol11$4,205
Ondansetron OdtOndansetron27$1,726
Levothyroxine Sodium53$1,670
Gabapentin65$1,131
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$1,131
Atorvastatin Calcium98$1,116
Diltiazem Hcl13$663
Metformin Hcl57$659
Tamsulosin Hcl30$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$22$19,72335 claims
Boehringer IngelheimJardiance$87$11,50413 claims
MerckJanuvia$263$10,57513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →